Objective: The optimal neoadjuvant chemoradiotherapy (CRT) regimen in esophageal cancer has not yet been defined. This study was aimed to compare the differences in pathologic response and survival between docetaxel/cisplatin and fluorouracil/cisplatin as neoadjuvant CRT in locally advanced esophageal squamous cell carcinoma (SCC). Methods: We retrospectively analyzed patients with thoracic esophageal SCC who received neoadjuvant CRT followed by esophagectomy from 2000 to 2014. After adjusting for sex, age, performance status, tumor length, tumor location and clinical TNM stage, 32 docetaxel/cisplatin-treated patients were matched to 62 patients who received fluorouracil/cisplatin at a ratio of 1:2. Treatment toxicity, pathologic complete response (pCR) and survival outcomes were compared between groups. Results: Baseline characteristics were well balanced between groups. The pCR rate in the docetaxel/cisplatin group was higher than that in the fluorouracil/cisplatin group but without significant difference (40.6% vs. 30.6%, P = 0.333). The 3-year overall survival rate in the docetaxel/cisplatin group was 64.9% versus 46.0% in the fluorouracil/cisplatin group (P = 0.039). There were no significant differences in incidence of treatment toxicity during CRT or surgical complications between groups, with the exception of Grade 3-4 hematologic toxicity (37.5% vs. 17.7%, P = 0.035), which was more frequent in the docetaxel/cisplatin group. Conclusions: Docetaxel/cisplatin might be associated with more favorable survival than fluorouracil/cisplatin in esophageal SCC treated with neoadjuvant CRT. Prospective validation is warranted.
Introduction
Esophageal cancer (EC) is the sixth leading cause of cancer-related death and remains a significant health problem worldwide, with 5-year overall survival (OS) rates of 15-34% for resectable disease (1, 2) . Based on randomized trials and meta-analyses results, neoadjuvant chemoradiotherapy (CRT) followed by surgery has been accepted as the standard treatment option for locally advanced EC (3) (4) (5) . The combination of fluorouracil and cisplatin (FP) is the most widely used chemotherapy regimen and is administered as neoadjuvant CRT, definitive CRT, or systemic chemotherapy for metastatic EC (4) (5) (6) . However, the survival of EC patients treated with the FP regimen remains unsatisfactory, with a 3-year OS rate of 27.0-47.5% in the neoadjuvant CRT setting (4) (5) (6) (7) (8) . In addition, it is relatively difficult to administer fluorouracil in the outpatient setting due to the need for a central venous catheter device. Therefore, more effective and more convenient regimens should be investigated to improve outcomes.
In recent years, many new regimens have shown promising effects for treating EC (3) (4) (5) (6) (9) (10) (11) (12) (13) (14) . Of them, docetaxel is a frequently used taxane with cytotoxic activity against EC, especially esophageal squamous cell carcinoma (SCC). In a randomized trial reported by Zhao et al., the docetaxel/cisplatin (DP) regimen led to higher response rates and better survival than FP in EC treated with definitive CRT (15) . A more recent study also confirmed the survival superiority of DP over FP in definitive setting (16) . However, the lack of prospective comparisons means that the benefit of DP over FP remains unclear in EC patients who received neoadjuvant CRT. Here, we aimed to compare the differences in treatment toxicity, pathologic response and survival outcomes between DP and FP as neoadjuvant CRT in locally advanced esophageal SCC through a matched case-control study.
Patients and methods

Patients
We retrospectively analyzed all consecutive EC patients who received neoadjuvant CRT followed by esophagectomy at Sun Yat-sen University Cancer Center between January 2000 and June 2014 (Fig. 1) . All patients had histologically confirmed thoracic esophageal SCC with Stage IIB or III disease according to the 6th TNM staging system of the American Joint Committee on Cancer (17) . Patients with history of previous or concomitant malignancy were excluded. Pretreatment evaluation included physical examination, standard laboratory tests, barium swallow test, endoscopy with biopsies, endoscopic ultrasonography (EUS), chest/abdominal computed tomography (CT) with contrast, pulmonary function test, and/or positron emission tomography (PET). Bone scans were performed selectively.
All patients received platinum-or taxane-based neoadjuvant chemotherapy regimen in our institution. For the most part, the choice of chemotherapy regimen has not been based on patient factors but rather on physician bias. Of them, 32 patients receiving DP regimen were defined as the study group and were matched to randomly selected patients who were treated with FP (control group) at a ratio of 1:2 according to the following variables: sex, age (within 5 years), PS score (0 vs. 1-2), tumor length (within 3 cm), tumor location (upper vs. middle vs. lower third), and clinical TNM stage (IIB vs. III). Two patients in DP group were matched to one control patient only, resulting in a control group of 62 patients. This study conformed to the provisions of the Declaration of Helsinki and was approved by our Institutional Review Boards. Radiation was delivered by three-dimensional conformal radiotherapy using 6-8 MV photon beams. Gross tumor volume (GTV) was defined as the primary tumor and positive lymph nodes on CT scan and EUS. Clinical target volume included GTV plus 3-cm margin in the caudal-cranial direction and a radial 1-cm margin, and elective lymph node regions. The prescribed dose was 40 Gy in 20 fractions, 5 days per week. All patients underwent re-staging~4-6 weeks after the completion of CRT. Esophagectomy was performed using a transthoracic esophagectomy (Ivor-Lewis) with two-field lymphadenectomy or traditional Sweet esophagectomy, depending on the operating surgeon. R0 resection was defined as the absence of malignancy on histopathologic examination of proximal, distal and circumferential margins. At our institution, the resected specimens were macroscopically and microscopically reviewed by one pathologist, and then it will be confirmed by another senior pathologist. The pathologic response was defined according to the tumor regression grade, as described by Mandard et al. (19) . In the absence of macroscopic tumor, the whole resected tissue was embedded in paraffin to make an assessment for the presence of any residual tumor. Pathologic complete response (pCR) was defined as the absence of residual tumor within the esophagus and lymph nodes.
Follow-up
Patients were followed every 3 months for the first year after surgery, every 4-6 months for the next 4 years, and then annually. Treatment toxicities were assessed according to the National Cancer Institute Common Toxicity Criteria version 3.0. Locoregional recurrences were defined as relapses of esophagus or regional lymph nodes, whereas distant recurrences were defined as any distant organ metastasis or non-regional lymph node recurrences. The data were updated in December 2015 for censored data analysis.
Statistical analysis
Categorical variables were compared using the chi-square test or Fisher's exact test. OS was determined from the date of diagnosis until death or last follow-up. Disease-free survival (DFS) was determined until recurrence, last follow-up, or death. Kaplan-Meier method was used to analyze survival, log-rank test was used to examine the differences between groups, and Cox proportional hazards regression model was used in multivariate analysis. Statistical analyses were performed using SPSS software (version 19.0; SPSS Inc., Chicago, IL). P < 0.05 was considered statistically significant.
Results
Patients
The characteristics of the study population are listed in Table 1 
Treatment toxicity
All patients successfully completed the full-dose radiotherapy, and no treatment-related Grade 5 toxicity occurred during neoadjuvant therapy. Full completion of two cycles of concurrent chemotherapy was achieved in 84.4% versus 88.7% of patients in the DP and FP group, respectively (P = 0.535). Table 2 lists the incidence of adverse events of any grade and Grade 3-4 toxicity during CRT per treatment group. There were no significant differences in incidence of treatment toxicity during CRT between groups, with the exception of anemia (P = 0.001) and Grade 3-4 hematologic toxicity (37.5% vs. 17.7%, P = 0.035), which were both more frequent in the docetaxel/cisplatin group.
All patients received esophagectomy within a median interval of 6.3 weeks (range, 4.0-9.9 weeks) after neoadjuvant treatment. Overall, 89 patients (94.7%) obtained R0 resection. A total of 12 patients underwent Sweet esophagectomy (10 patients in FP group and 2 in DP group), and the remaining 82 patients underwent IvorLewis esophagectomy. As shown in Table 2 , there were no significant differences in incidence of surgical complications or in-hospital mortality between groups.
Pathology
Within the whole cohort, pCR was achieved in 32 patients (34.0%) after esophagectomy. Patients with non-pCR had the following characteristics: T0N1M0, 1.1% (n = 1); Stage I, 8.5% (n = 8); Stage II, 29.8% (n = 28); Stage III, 22.3% (n = 21); and Stage IV, 4.3% (n = 4). The pCR rate was 40.6% (95% confidence interval (CI), 23.6-57.6%) in the DP group versus 30.6% (95% CI, 19.2-42.0%) in the FP group, respectively (P = 0.333).
Follow-up and survival
The median follow-up was 31.2 months (range, 3.3-152.6 months) for the whole group. The median follow-up period for survivors was 62.5 months (range, 20.7-83.2 months) for the DP group and 65.0 months (range, 27.8-152.6 months) for the FP group, respectively. At this analysis, 66 patients (70.2%) had died, including 40 who died from disease progression, 16 who died from surgery-related complications, 6 who died from other causes without tumor, 1 who died from a second primary tumor, and 3 patients who died from unknown causes. During the follow-up period, 44 patients experienced disease recurrences, including 20 who had locoregional recurrence and 38 who had distant failure. The incidence of locoregional recurrence was lower in the DP group than that in the FP group but without significant difference (15.6% vs. 24.2%, P = 0.43). In addition, 31.3% of patients in the DP group had distant recurrences versus 45.2% in the FP group (P = 0.268).
At 3 years, the DP group was associated with significantly better OS than FP group (64.9% vs. 46.0%), with a median OS of 54.1 versus 31.1 months, respectively (P = 0.039; Fig. 2A ). The median DFS was also significantly more favorable in the DP group when compared with FP group (24.2 vs. 10.0 months), with 3-year DFS rates of 45.9% versus 24.2%, respectively (P = 0.044; Fig. 2B ).
Univariate analysis revealed that age, histologic grade, chemotherapy regimen and pathologic response to neoadjuvant CRT were correlated with either OS or DFS (Table 3) . The further multivariate analysis demonstrated that age (P = 0.007), histologic grade (P = 0.001), and pathologic response (P < 0.001) were independent prognostic factors for OS. Moreover, age ≥ 55 years (P < 0.001), well differentiated SCC (P = 0.001), and pCR (P < 0.001) were also favorable independent prognostic factors for DFS.
Discussion
Although neoadjuvant CRT followed by surgery has been considered the standard care for localized EC of both histologic subtypes, the optimal chemotherapy regimen remains controversial. This matched case-control study indicated that the DP regimen was associated with significantly better survival outcomes in esophageal SCC when compared with traditional FP regimen.
Both paclitaxel and docetaxel are active against EC and demonstrate encouraging efficacy and safety profiles. Nevertheless, literature on the effectiveness and toxicity of the taxane-based regimens compared with standard FP is limited. Adelstein et al. compared paclitaxel/cisplatin with FP in 102 patients with EC who received neoadjuvant CRT and showed that the paclitaxel-based treatment produced increased toxicity with no improvement in survival or locoregional control (13) . In contrast, Boggs et al. suggested that, compared to FP, paclitaxel-based regimens resulted in similar pCR rates, progression-free survival, and OS but produced less hematological toxicity (12). Hsu et al. reported the clinical results following paclitaxel/cisplatin versus FP use in both a definitive CRT and a neoadjuvant setting (20) . Disappointingly, although the paclitaxel/cisplatin group had better DFS than FP in the definitive setting, paclitaxel/ cisplatin it did not improve survival in the neoadjuvant setting.
Collectively, these findings suggest that the survival benefit of paclitaxel-based regimens over traditional FP has not been defined.
Compared with paclitaxel, another taxane, docetaxel, is associated with less neurotoxicity and is better tolerated when combined with cisplatin. Accordingly, multiple studies have investigated the role of docetaxel combined with radiotherapy in either definitive or neoadjuvant CRT settings (15, 16, (21) (22) (23) (24) (25) (26) (27) . However, no study has directly compared DP with FP in the neoadjuvant CRT setting. The pCR rates after docetaxel-based CRT were relatively higher (>40%) in studies that included a higher proportion of esophageal SCC, which may be due to the high sensitivity of esophageal SCC to docetaxel (11, (22) (23) (24) (25) (26) (27) . In our study, the pCR rate in the FP group (30.6%) was consistent with that reported previously (20-40%) (4) (5) (6) (7) (8) . Compared with FP, the DP group had a nonsignificantly higher pCR rate (40.6%) and significantly more favorable survival in our study. The non-significant difference in pCR rates between the two regimens may be due to the limited number of patients. In addition to survival benefit, docetaxel can be conveniently administered in the outpatient setting and requires fewer days to complete. Thus, an advantage of DP over FP has been suggested by the current study, and prospective validation is warranted to compare these two regimens directly.
The toxicity profiles of docetaxel and fluorouracil are very different. In our study, the occurrence of Grade 3-4 hematologic toxicity was more frequent in the DP group than FP group, which was in agreement with previous reports (15, 16) . Nevertheless, the hematologic toxicity in the DP group was tolerable and manageable, and it did not compromise the performance of radiotherapy and subsequent esophagectomy. Therefore, such chemotherapy-related toxicity should be justified because improved survival could be achieved with the DP regimen. In the CROSS trial, neoadjuvant CRT significantly improved not only locoregional control, but also distant disease control compared with surgery alone (28) . The rate of total recurrences of the whole group in our study is similar to that of the CROSS trial. Compared with the FP group, both of locoregional and distant recurrences were less frequent in the DP group (24.2% vs. 15.6%; 45.2% vs. 31.3%, respectively). The non-significant difference of recurrence rates between groups potentially owing to the limited number of patients. It has been well demonstrated that pCR is associated with reduced risk of recurrences and better survival in EC (7) . Therefore, the higher local control in the DP group could be attributed to the higher pCR rate, whereas the better distant disease control may have been caused by the direct systemic effect of the DP regimen. Studies with larger sample sizes are needed to confirm these results.
This study did have some limitations. Firstly, the number of patients was relatively small and a larger sample would be required to make the conclusions more robust. Secondly, selection bias is inevitable due to the retrospective nature of this single-institutional study, despite we use matching method to mitigate this limitation. For instance, several baseline characteristics were not very well balanced between the two groups. Moreover, more patients in the FP group (10/62) were treated by Sweet technique than in the DP group (2/32). Although the locoregional recurrence rate was not significantly different between the two groups (15.6% in DP group vs. 24.2% in FP group, P = 0.43), this difference may have resulted in an additional bias regarding the poor survival of the FP group. Thirdly, the toxicity information was not collected prospectively and was limited to the medical records, which may affect the accuracy of toxicity evaluation. In addition, PET/CT scans were not available for the majority of patients in the current study, which may influence the accuracy of clinical staging. 
